Home
|
Learning Center
|
中文版
Publications
站内成果搜索:
搜索
Axisymmetric force-free magnetosphere in the exterior of a neutron star - II. Maximum storage and open field energies
Axisymmetric black holes allowing for separation of variables in the Klein-Gordon and Hamilton-Jacobi equations
Axisymmetric plane vibration analysis of polar-anisotropic disks
Axisymmetric semi-analytical finite elements for modelling waves in buried/submerged fluid-filled waveguides
Axisymmetric Arc Sliding Method of Basal Heave Stability Analysis for Braced Circular Excavations
Axisymmetric nonstationary elastic contact problem for conforming surfaces
Axisymmetric spheroidal modes of neutron stars magnetized with poloidal magnetic fields
Axis II Personality Disorders Are Linked to an Adverse Course of Bipolar Disorder
Axisymmetric flow of Casson fluid by a swirling cylinder
Axisymmetric global Alfven eigenmodes within the ellipticity-induced frequency gap in the Joint European Torus
Axisymmetric Contact Problem for a Flattened Cell: Contributions of Substrate Effect and Cell Thickness to the Determination of Viscoelastic Properties by Using AFM Indentation
Axisymmetric lattice Boltzmann method for non-Newtonian flows
Axisymmetric Boussinesq problem of a transversely isotropic half space with surface effects
Axisymmetric rim instability of water droplet impact on a super-hydrophobic surface
Axis of serotonin -pERK-YAP in liver regeneration.
Axis-coupled trajectory generation for chains of integrators through smoothing splines
Axis实现的Web Services运行概况浅述
阿西替尼
阿西替尼治疗转移性肾癌研究现状
Axitinib for the treatment of advanced renal cell carcinoma
Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial
Axitinib or Bevacizumab Plus FOLFIRI or Modified FOLFOX-6 After Failure of First-Line Therapy for Metastatic Colorectal Cancer: A Randomized Phase II Study
Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial
Axitinib Affects Cell Viability and Migration of a Primary Foetal Lung Adenocarcinoma Culture
Axitinib for the Treatment of Metastatic Renal Cell Carcinoma Recommendations for Therapy Management to Optimize Outcomes
Axitinib Improves Radiotherapy in Murine Xenograft Lung Tumors
Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial
Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis
Axitinib for the treatment of advanced non-small-cell lung cancer
Axitinib alone or in combination with chemotherapeutic drugs exerts potent antitumor activity against human gastric cancer cells in vitro and in vivo
Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies
阿西替尼的合成
阿细跳月文化品牌的发展及其引发的思考
阿西替尼的合成工艺研究
Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells
Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study
阿西替尼治疗转移性肾细胞癌的不良反应及护理
阿西替尼中间体(E)-6-碘-3-(2-(吡啶-2-基)乙烯基)-1-(四氢-2H-吡喃-2-基)-1H-吲唑的合成研究
Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma
Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma
Axitinib blocks Wnt/beta-catenin signaling and directs asymmetric cell division in cancer
Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian "Real-World" SAX Study
Axitinib-induced proteinuria and efficacy in patients with metastatic renal cell carcinoma
阿西替尼与多柔比星协同抗肿瘤活性研究
Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment
Axitinib In Advanced, Treatment-Experienced Renal Cell Carcinoma
Axitinim believe in Second-Line Therapy
Axitinib for the treatment of renal cell carcinoma receives US FDA approval
Axitinib (Inlyta) for Advanced Renal Cell Carcinoma
Axitinib
Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: A randomized phase 2 study
Axitinib Controlled Metastatic Renal Cell Carcinoma for 5 Years
Axitinib for preoperative downstaging of renal cell carcinoma with sarcomatoid differentiation and direct invasion of the duodenum and inferior vena cava: a case report
Axitinib in advanced renal-cell carcinoma
Axitinib (AG-013736), an Oral Specific VEGFR TKI, Shows Potential Therapeutic Utility Against Cholangiocarcinoma
Axitinib plasma pharmacokinetics and ethnic differences
Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation
Axitinib for renal cell carcinoma
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer
Axitinib-a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor
Axitinib in metastatic renal carcinomas: update of knowledge about side effects
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study
Axitinib dose titration: what's the limiting factor?
Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial
阿西土陶文创产品设计研究
阿昔替尼联合塞来昔布体外抗胃癌细胞BGC-823和SNU-5增殖及抗血管生成作用观察
阿西替尼眼用生物可降解药膜的制备
阿昔替尼与索拉非尼一线治疗晚期肾癌的临床疗效
Axitinib sensitization of high Single Dose Radiotherapy
Axitinib for the first line therapy of renal cancer: failure of a trial or failure of a strategy?
Axitinib modulates hypoxia-induced blood-retina barrier permeability and expression of growth factors
Axitinib in the treatment of metastatic renal cell carcinoma
Axitinib in metastatic renal cell carcinoma: beyond the second-line setting
Axitinib inhibits retinal and choroidal neovascularization in in vitro and in vivo models
Axitinib: A Review in Advanced Renal Cell Carcinoma
Axitinib in metastatic renal cell carcinoma: patient characteristics and treatment patterns in US community oncology centers
Axitinib in renal cell carcinoma: now what do we do?
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
Axitinib attenuates intraplaque angiogenesis, haemorrhages and plaque destabilization in mice
阿西土陶产品设计文献综述
Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial